<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01616615</url>
  </required_header>
  <id_info>
    <org_study_id>ASAP</org_study_id>
    <secondary_id>2012-000622-22</secondary_id>
    <nct_id>NCT01616615</nct_id>
  </id_info>
  <brief_title>Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation</brief_title>
  <acronym>ASAP</acronym>
  <official_title>Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sara Varea</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundacion Clinic per a la Recerca Biomédica</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To establish wether a prophylactic intervention from first trimester with low-dose of aspirin&#xD;
      improves trophoblastic invasion evaluated at third trimester in women defined as high-risk by&#xD;
      abnormal uterine artery Doppler at first trimester&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Uterine artery mean pulsatility</measure>
    <time_frame>at 28 weeks of gestation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-eclampsia</measure>
    <time_frame>delivery</time_frame>
    <description>pre-eclampsia defined as: diastolic blood pressure (DBP)&gt; = 90 mmHg) or systolic (SBP)&gt; = 140 mmHg on two separated determinations (&gt; 4h) with proteinuria&gt; 300 mg/24 h -Gestational age at debut of preeclampsia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Severe preeclampsia</measure>
    <time_frame>at delivery</time_frame>
    <description>Severe preeclampsia defined as: preeclampsia criteria + DBP&gt; = 110 mmHg, proteinuria&gt; 5g/24h, oligouria (&lt;400 ml/24h), neurological symptoms (brain or visual), acute pulmonary edema (gasometric and radiological criteria), persistent epigastric pain, abnormal liver function (AST or Alanine aminotransferase(ALT)&gt; 70 IU), analytical signs of hemolysis (LDH&gt; 700 U / L) and / or thrombocytopenia (&lt;100.000/ml).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intrauterine Growth Retardation</measure>
    <time_frame>at delivery</time_frame>
    <description>Intrauterine Growth Retardation: birth weight below the 10th percentile of our population + pulsatility index in umbilical artery in the third trimester (on two separate occasions &gt;48h)above the 95th percentile.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Significant neonatal morbidity</measure>
    <time_frame>at delivery</time_frame>
    <description>Significant neonatal morbidity (convulsions, intraventricular hemorrhage&gt; grade III, periventricular leukomalacia, hypoxic-ischemic encephalopathy, abnormal electroencephalogram, necrotizing enterocolitis, acute renal failure (serum creatinine&gt; 1.5 mg / dl) or heart failure (requiring inotropic agents</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>number of cesarean</measure>
    <time_frame>at delivery</time_frame>
    <description>Emergent cesarean section due to fetal wellbeing loss Birth weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Neonatal acidosis</measure>
    <time_frame>at delivery</time_frame>
    <description>Neonatal acidosis (arterial pH &lt;7.10 + Base excess(BE)&gt; 12 milliequivalent (mEq) / L)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perinatal mortality</measure>
    <time_frame>28 days post partum</time_frame>
    <description>Perinatal mortality (&gt; 22 weeks gestation, &lt;28 days postpartum)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Days in the Neonatal Intensive Care Unit</measure>
    <time_frame>28 days post partum</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">190</enrollment>
  <condition>Placental Insufficiency</condition>
  <arm_group>
    <arm_group_label>ASPIRIN</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>150 mg milligram(s)/ day oral use</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PLACEBO</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Aspirin</intervention_name>
    <description>150 mg/day oral use</description>
    <arm_group_label>ASPIRIN</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>1 capsule / day oral use</description>
    <arm_group_label>PLACEBO</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients over 18 years old attending for routine ultrasound at first trimester of&#xD;
             pregnancy between 11 and 14 weeks of gestation (Crown-to rump length 45-48mm)&#xD;
&#xD;
          -  Single gestation&#xD;
&#xD;
          -  Mean pulsatility index of the uterine arteries above the 95th percentile for our&#xD;
             population&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pre-existing hypertension, renal or cardiovascular disease&#xD;
&#xD;
          -  previous history of pre-eclampsia&#xD;
&#xD;
          -  Pregestational diabetes&#xD;
&#xD;
          -  Systemic lupus Erythematosus&#xD;
&#xD;
          -  Gastric ulcer&#xD;
&#xD;
          -  Acetylsalicylic acid or lactose hypersensitivity&#xD;
&#xD;
          -  Bleeding disorders&#xD;
&#xD;
          -  Fetal disorders (including chromosomal abnormalities)&#xD;
&#xD;
          -  Administration of low molecular weight heparin&#xD;
&#xD;
          -  Concomitant treatment with aspirin&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>FRANCESC FIGUERAS, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic of Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Clinic of Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Dexeus</name>
      <address>
        <city>Barcelona</city>
        <zip>08028</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <study_first_submitted>June 8, 2012</study_first_submitted>
  <study_first_submitted_qc>June 8, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 12, 2012</study_first_posted>
  <last_update_submitted>August 17, 2015</last_update_submitted>
  <last_update_submitted_qc>August 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Fundacion Clinic per a la Recerca Biomédica</investigator_affiliation>
    <investigator_full_name>Sara Varea</investigator_full_name>
    <investigator_title>Clinical Trial Manager</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Placental Insufficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

